Remove Generic Medicine Remove Labelling Remove Packaging
article thumbnail

Standards support medicines supply chain resilience and the future of quality

Quality Matters

Quality across the product lifecycle The role of standards goes far beyond the drug manufacturing process – from the sourcing of raw materials to packaging, labeling, distribution, and point-of-care administration – to help ensure quality across the pharmaceutical product lifecycle.

article thumbnail

Essential elements of a strong, global medicines supply chain

Quality Matters

Quality standards and related tools – supported by appropriate regulatory capability and enforcement – can help promote quality across the pharmaceutical product lifecycle, from the sourcing of active and inactive ingredients to packaging, labeling, distribution, and point-of-care administration.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

World Standards Day: Recognizing How Standards Enable a Strong Medicines Supply Chain

Quality Matters

With this extensive system in place, patients can trust that medicines with the same name will be consistent in quality no matter who manufactures it or where in the world it is made. Since manufacturers know the precise quality specifications, standards help make the approval process for generic medicines more efficient.

article thumbnail

Parallel import of medicinal products: regulatory update

European Pharmaceutical Review

This is due to the regulatory requirements imposed on parallel imported medicinal products in various Member States, the fulfilment of which often requires repackaging. Repackaging a medicinal product… means that the trademark is reapplied by an entity other than the trademark proprietor.”

article thumbnail

What happened to all the antibiotics?

pharmaphorum

These include allowing the exceptional supply of certain medicines that may not be authorised in a particular Member State or granting full or partial exemptions to certain labelling and packaging requirements to address severe problems in respect of the availability of some medicines.”

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

Certain groups of individuals may then not trust that the medicines have been produced with them in mind and may be highly sceptical of the resulting evidence base and prescribing label of medicines. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.

Packaging 143